2022
Platelet in thrombo-inflammation: Unraveling new therapeutic targets
Sharma S, Tyagi T, Antoniak S. Platelet in thrombo-inflammation: Unraveling new therapeutic targets. Frontiers In Immunology 2022, 13: 1039843. PMID: 36451834, PMCID: PMC9702553, DOI: 10.3389/fimmu.2022.1039843.Peer-Reviewed Original ResearchMeSH KeywordsBlood PlateletsCOVID-19Endothelial CellsFemaleHumansInflammationIschemic StrokePregnancyConceptsRole of plateletsViral infectionPlatelet activationCoagulation pathwayThrombo-inflammatory disordersAcute ischemic strokeContribution of plateletsAnti-inflammatory potentialThrombo-inflammatory diseasesCoronavirus disease 2019Sickle cell diseaseNon-pathologic conditionsNew therapeutic targetsRecruitment of leukocytesPathologic platelet activationPlatelet surface receptorsFormation of thrombiInitial platelet activationSuperficial thrombophlebitisAntiphospholipid syndromeIschemic strokeMicrovascular thrombosisClinical manifestationsInflammatory processCell disease
2020
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI, Halene S, Martin KA, Chun HJ, Hwa J. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews Cardiology 2020, 18: 194-209. PMID: 33214651, PMCID: PMC7675396, DOI: 10.1038/s41569-020-00469-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdministration, InhalationAnticoagulantsBlood Coagulation DisordersBlood Platelet DisordersCOVID-19COVID-19 Drug TreatmentEndothelium, VascularEndothelium-Dependent Relaxing FactorsEpoprostenolHeart Disease Risk FactorsHumansIloprostInflammationNitric OxidePlatelet Aggregation InhibitorsSARS-CoV-2Systemic Inflammatory Response SyndromeThrombosisThrombotic MicroangiopathiesVascular DiseasesVasodilator AgentsVenous ThromboembolismConceptsCardiovascular risk factorsRisk factorsCOVID-19Severe acute respiratory syndrome coronavirus 2Pre-existing cardiovascular diseaseAcute respiratory syndrome coronavirus 2Traditional cardiovascular risk factorsAcute respiratory distress syndromeRespiratory syndrome coronavirus 2Respiratory distress syndromeManagement of patientsSyndrome coronavirus 2COVID-19 pathologyCoronavirus disease 2019Potential therapeutic strategyCytokine stormEndothelial dysfunctionThrombotic complicationsDistress syndromeExcessive inflammationCoronavirus 2Severe outcomesAdvanced ageCardiovascular diseaseDisease 2019